Reduced-intensity conditioning (RIC) regimens in myeloid malignancies.
| Study Group . | Regimen* . | Disease Category . | Median Age (yrs) . | No. of Patients . | Donor Type . | Stem Cell Source . | Acute GVHD III–IV . | Chronic GVHD . | OS . | RFS . | NRM . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: ~, Estimated from figure; NA, not available; MRD, HLA-matched related donor; MMRD, HLA-mismatched related donor; URD, unrelated donor; BM, bone marrow stem cells; PBSC, peripheral blood stem cells; Flu, fludarabine; TBI, total body irriadiation; ATG, anti-thymocyte globulin; | |||||||||||
| *Regimens: 131I + Flu/TBI = 131I-anti-CD45 Antibody + Flu/TBI FAI = Flu 120 mg/m2 + cytarabine 1 g/m2 + idarubicin 36 mg/m2 FB + ATG = Flu 150 mg/m2 + Busulfan 8 mg/kg + ATG 20–40 mg/kg FB2 = Flu 150–160 mg/m2 + iv Busulfan 6.4 mg/kg FBC = Flu 150 mg/m2 + Busulfan 8 mg/kg + Alemtuzumab 100 mg Flu/TBI = Flu 90 mg/m2 + TBI 2 Gy FM = Flu 25–30 mg/m2 + melphalan 140 or 180 mg/m2 FMC = Flu 150 mg/m2 + melphalan 140 mg/m2 + Alemtuzumab 100 mg GO + FM = Gemtuzumab ozogamicin + FM | |||||||||||
| **TBI < 3 Gy or Bu ≤ 8 mg/kg | |||||||||||
| †TBI 2–4 Gy or Bu 8–10 mg/kg | |||||||||||
| ‡TBI ≤ 6 Gy or Bu ≤ 8 mg/kg | |||||||||||
| MDACC30 | FAI | AML + MDS | 61 | 32 | 81% MRD; 19% MMRD | 84% BM; 16% PBSC | 11% | 27% | 30% | 19% | ~18% (1-year) |
| MDACC30 | FM | AML + MDS | 54 | 62 | 40% MRD; 47% URD, 13% MMRD | 42% BM; 58% PBSC | 19% | 39% | 35% | 32% | ~21% (1-year) |
| FHCRC11 | 131I + Flu/TBI | AML + MDS | 61 | 33 | 30% MRD; 70% URD | 100% PBSC | NA | NA | NA | 55% | 12% (day 100) |
| MDACC13 | GO + FM | AML + MDS | NA | 52 | NA | NA | NA | NA | 40% | 30% | NA |
| FHCRC31 | Flu/TBI | AML + MDS | 62 | 38 | 68% MRD; 32% URD | 95% PBSC; 5% BM | 22% | 55% | 27% | 28% | 22% (1-year) |
| King’s College7 | FBC | AML + MDS | 56–52 | 62 | 39% MRD; 61% URD | 66% PBSC; 34% BM | 9% | ~20% | 74% | 62% | 15% (1-year) |
| Queen Elizabeth Hospital8 | FMC | AML + MDS | 52 | 76 | 46% MRD; 54% URD | 68% PBSC; 32% BM | 0% | NA | 41% | 37% | 19% (1-year) |
| University of Chicago9 | FMC | AML + MDS | 52 | 52 | 44% MRD; 49% URD | NA | 10% | 18% | 48% | 38% | 33% (1-year) |
| Seattle Consortium27 | Flu/TBI | AML | 58 | 122 | 48% MRD; 52% URD | 95% PBSC; 5% BM | 12% | 36% | 48% | 44% | 14% (1-year) |
| Chaim Sheba Med. Center32 | FB2 | AML + MDS | 57 | 41 | 34% MRD; 66% URD | NA | 8% | 31% | 47% | 43% | 8% (cumulative) |
| EBMT28 | TBI or Bu** | AML | 57 | 315 | 100% MRD | 90% PBSC; 10% BM | 8% | 48% | 47% | 40% | 18% (2-years) |
| EBMT29 | TBI or Bu† | AML + MDS | 56 | 215 | 100% MRD | 87% PBSC; 13% BM | 15% | 45% | 41% | 33% | 20% (1-year) |
| Seattle Consortium33 | Flu/TBI | CML | 58 | 24 | 100% MRD | 100% PBSC | 12% | 32% | 54% | 54% | 21% (cumulative) |
| Hadassah-Hebrew Univ.35 | FB + ATG | CML | 35 | 24 | 79% MRD; 21% URD | 100% PBSC | 29% | 55% | 85% | 85% | 0% (day 100) |
| EBMT36 | TBI or Bu‡ | CML | 50 | 186 | 67% MRD; 25% URD | 72% PBSC; 28% BM | 32% | 43% | 58% | 37% | 23.3% (2-year) |
| Study Group . | Regimen* . | Disease Category . | Median Age (yrs) . | No. of Patients . | Donor Type . | Stem Cell Source . | Acute GVHD III–IV . | Chronic GVHD . | OS . | RFS . | NRM . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: ~, Estimated from figure; NA, not available; MRD, HLA-matched related donor; MMRD, HLA-mismatched related donor; URD, unrelated donor; BM, bone marrow stem cells; PBSC, peripheral blood stem cells; Flu, fludarabine; TBI, total body irriadiation; ATG, anti-thymocyte globulin; | |||||||||||
| *Regimens: 131I + Flu/TBI = 131I-anti-CD45 Antibody + Flu/TBI FAI = Flu 120 mg/m2 + cytarabine 1 g/m2 + idarubicin 36 mg/m2 FB + ATG = Flu 150 mg/m2 + Busulfan 8 mg/kg + ATG 20–40 mg/kg FB2 = Flu 150–160 mg/m2 + iv Busulfan 6.4 mg/kg FBC = Flu 150 mg/m2 + Busulfan 8 mg/kg + Alemtuzumab 100 mg Flu/TBI = Flu 90 mg/m2 + TBI 2 Gy FM = Flu 25–30 mg/m2 + melphalan 140 or 180 mg/m2 FMC = Flu 150 mg/m2 + melphalan 140 mg/m2 + Alemtuzumab 100 mg GO + FM = Gemtuzumab ozogamicin + FM | |||||||||||
| **TBI < 3 Gy or Bu ≤ 8 mg/kg | |||||||||||
| †TBI 2–4 Gy or Bu 8–10 mg/kg | |||||||||||
| ‡TBI ≤ 6 Gy or Bu ≤ 8 mg/kg | |||||||||||
| MDACC30 | FAI | AML + MDS | 61 | 32 | 81% MRD; 19% MMRD | 84% BM; 16% PBSC | 11% | 27% | 30% | 19% | ~18% (1-year) |
| MDACC30 | FM | AML + MDS | 54 | 62 | 40% MRD; 47% URD, 13% MMRD | 42% BM; 58% PBSC | 19% | 39% | 35% | 32% | ~21% (1-year) |
| FHCRC11 | 131I + Flu/TBI | AML + MDS | 61 | 33 | 30% MRD; 70% URD | 100% PBSC | NA | NA | NA | 55% | 12% (day 100) |
| MDACC13 | GO + FM | AML + MDS | NA | 52 | NA | NA | NA | NA | 40% | 30% | NA |
| FHCRC31 | Flu/TBI | AML + MDS | 62 | 38 | 68% MRD; 32% URD | 95% PBSC; 5% BM | 22% | 55% | 27% | 28% | 22% (1-year) |
| King’s College7 | FBC | AML + MDS | 56–52 | 62 | 39% MRD; 61% URD | 66% PBSC; 34% BM | 9% | ~20% | 74% | 62% | 15% (1-year) |
| Queen Elizabeth Hospital8 | FMC | AML + MDS | 52 | 76 | 46% MRD; 54% URD | 68% PBSC; 32% BM | 0% | NA | 41% | 37% | 19% (1-year) |
| University of Chicago9 | FMC | AML + MDS | 52 | 52 | 44% MRD; 49% URD | NA | 10% | 18% | 48% | 38% | 33% (1-year) |
| Seattle Consortium27 | Flu/TBI | AML | 58 | 122 | 48% MRD; 52% URD | 95% PBSC; 5% BM | 12% | 36% | 48% | 44% | 14% (1-year) |
| Chaim Sheba Med. Center32 | FB2 | AML + MDS | 57 | 41 | 34% MRD; 66% URD | NA | 8% | 31% | 47% | 43% | 8% (cumulative) |
| EBMT28 | TBI or Bu** | AML | 57 | 315 | 100% MRD | 90% PBSC; 10% BM | 8% | 48% | 47% | 40% | 18% (2-years) |
| EBMT29 | TBI or Bu† | AML + MDS | 56 | 215 | 100% MRD | 87% PBSC; 13% BM | 15% | 45% | 41% | 33% | 20% (1-year) |
| Seattle Consortium33 | Flu/TBI | CML | 58 | 24 | 100% MRD | 100% PBSC | 12% | 32% | 54% | 54% | 21% (cumulative) |
| Hadassah-Hebrew Univ.35 | FB + ATG | CML | 35 | 24 | 79% MRD; 21% URD | 100% PBSC | 29% | 55% | 85% | 85% | 0% (day 100) |
| EBMT36 | TBI or Bu‡ | CML | 50 | 186 | 67% MRD; 25% URD | 72% PBSC; 28% BM | 32% | 43% | 58% | 37% | 23.3% (2-year) |